DSIP FDA & Regulatory Status (2026)
Published reporting only; not an independently verified live regulatory determination. Sources and review dates are shown for each field.
Author: Chad E. · Last reviewed: 2026-10-17
- FDA compounding category
- Not yet reviewed
- PCAC review and vote
- July 24, 2026: Emideltide (DSIP) was not recommended for inclusion. The vote is advisory. Source post
Reviewed: 2026-10-17 - 503A bulks list status
- The July 24 coverage reports a negative advisory recommendation, not a final FDA bulks-list decision. Source post
Reviewed: 2026-10-17 - FDA-approved drug
- Not yet reviewed
- WADA status
- Not yet reviewed
Recent developments
- Apex Peptides, Federal Agents, and What the September 23 Raid Actually Tells Us About the RUO Sector
- The FDA Voted. Now What? The Complete Road Map to What Happens After the PCAC Peptide Decision
- FDA Advisory Panel Day 2 Results: Semax and Epitalon Recommended, Emideltide Rejected: Full Two-Day Scorecard
- FDA Advisory Panel Votes to Recommend BPC-157, TB-500, KPV, and MOTS-c for Compounding (2026)
- 503A vs. 503B: How Peptides Fit Into the U.S. Compounding Framework in 2026 and Beyond
Sourced questions
What did the PCAC vote on DSIP?
July 24, 2026: Emideltide (DSIP) was not recommended for inclusion. The vote is advisory.
Is DSIP on the 503A bulks list?
The July 24 coverage reports a negative advisory recommendation, not a final FDA bulks-list decision.
Encyclopedia entry · State-law reference
Research use only. Not for human consumption. This page summarizes public regulatory information and is not legal advice.